NCT07375901

the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration

The State of the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Patients With Exudative Age-Related Macular Degeneration

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: The Filatov Institute of Eye Diseases and Tissue Therapy · Academic / Other
• Sex: All
• Age: 47 Years – 88 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the status of the blood-aqueous barrier by objectively measuring protein concentration in the aqueous humor using laser flare photometry (LFP) in patients with exudative age-related macular degeneration (AMD) undergoing anti-angiogenic therapy.

Detailed description

All patients were assigned to two groups. The first group was administered intravitreal injections of 2 mg (0.05 mL) aflibercept, while the second group received 6 mg (0.05 mL) brolucizumab. The regimen of treatment in both groups was treat-and-extend

Conditions

• AMD

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	laser flare photometry before intravitreal injection	The first group was administered intravitreal injections of 2 mg (0.05 mL) aflibercept The second group received 6 mg (0.05 mL) brolucizumab. Objectively measuring protein concentration in the aqueous humor using laser flare photometry (LFP).

Timeline

• Start date: 2021-03-25
• Primary completion: 2023-04-15
• Completion: 2024-04-10
• First posted: 2026-01-29
• Last updated: 2026-01-29

Locations

1 site across 1 country: Ukraine